Charles River Laboratories
251 Ballardvale Street
Wilmington
Massachusetts
01887
United States
Tel: 877-274-8371
Website: http://www.criver.com/
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
396 articles with Charles River Laboratories
-
Charles River Laboratories Schedules Second-Quarter 2021 Earnings Release and Conference Call
7/13/2021
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2021 financial results on Wednesday, August 4 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 4 th , at 9:30 a.m. ET.
-
Charles River Laboratories Completes Acquisition of Vigene Biosciences
6/29/2021
Charles River Laboratories International, Inc. announced that it has completed the previously announced acquisition of Vigene Biosciences, Inc. for $292.5 million in cash, subject to customary closing adjustments.
-
Charles River Laboratories Announces Long-Term Solar Contract for North American Operations
6/7/2021
Charles River Laboratories International, Inc. announced a long-term solar energy contract to address the entirety of the Company’s North American electric power requirements with clean, renewable energy by 2023.
-
Charles River Laboratories to Participate in June Investor Conferences
5/28/2021
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including: Jefferies Virtual Healthcare Conference on Tuesday, June 1 st , at 10:00 a.m. ET; William Blair 41 st Annual Growth Stock Conference on Wednesday, June 2 nd , at 11:00 a.m. ET; and
-
Charles River Laboratories to Acquire Vigene Biosciences to Enhance Gene Therapy Capabilities
5/17/2021
Further Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy CDMO Sector
-
Charles River Laboratories Announces First-Quarter 2021 Results
5/4/2021
– First-Quarter Revenue of $824.6 Million – – First-Quarter GAAP Earnings per Share of $1.20 and Non-GAAP Earnings per Share of $2.53 – – Updates 2021 Guidance –
-
Charles River Laboratories Schedules First-Quarter 2021 Earnings Release and Conference Call
4/13/2021
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2021 financial results on Tuesday, May 4th, before the market opens. A conference call has been scheduled to discuss this information on Tuesday, May 4th, at 9:00 a.m. ET.
-
Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities
4/6/2021
Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence’s artificial intelligence platform for molecular property prediction,
-
Charles River Laboratories Acquires Retrogenix
3/31/2021
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Retrogenix Limited, an early-stage contract research organization (CRO) providing specialized bioanalytical services utilizing its proprietary cell microarray technology.
-
Charles River Laboratories Completes the Acquisition of Cognate BioServices
3/29/2021
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million, subject to customary closing adjustments.
-
Charles River Laboratories Announces Closing of Senior Notes Offering - Mar 23, 2021
3/23/2021
Charles River Laboratories International, Inc. announced that it has closed its previously announced offering of $500 million in aggregate principal amount of its 3.750% senior notes due 2029 and $500 million in aggregate principal amount of its 4.000% senior notes due 2031 in an unregistered offering.
-
Virpax to Initiate Investigational New Drug (IND) Enabling Studies for Epoladerm(TM)
3/10/2021
Virpax Pharmaceuticals Inc. (NASDAQ:VRPX), today announced that it has signed an agreement with Charles River Laboratories to initiate preclinical studies of Epoladerm
-
Charles River Laboratories Prices $1 Billion of Senior Notes
3/9/2021
Charles River Laboratories International, Inc. (NYSE: CRL) announced that on March 8, 2021 it priced its private offering (the “offering”) of $500 million in aggregate principal amount of 3.750% senior notes due 2029 (the “2029 notes”) and $500 million in aggregate principal amount of 4.000% senior notes due 2031 (the “2031 notes” and, together with the 2029 notes, the “notes”).
-
Charles River Laboratories to Present at Barclays Global Healthcare Conference
3/8/2021
Charles River Laboratories International, Inc. announced that it will virtually present at the Barclays Global Healthcare Conference on Wednesday, March 10th, at 10:20 a.m. ET.
-
Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
2/17/2021
Acquiring Cognate Bioservices - – Significantly Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector – – Combines Cognate’s Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution from Discovery through CGMP Manufacturing – WILMINGTON, Mass.--( BUSINESS WIRE )-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate Bio
-
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance
2/17/2021
Charles River reports – Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion – – Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 –
-
Charles River Laboratories will acquire Cognate BioServices in an $875 million cash deal that will significantly expand the company’s capabilities in the high-growth cell and gene therapy sector.
-
Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening
1/28/2021
Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening
-
Charles River Partners with JADE Biomedical to Expand Biologics Capabilities
1/14/2021
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with JADE Biomedical (JADE) , a provider of end-to-end quality management services for the biopharmaceutical industry. The partnership will expand Charles River’s biologics testing capabilities
-
Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients
1/11/2021
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001 , a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.